Bio-Techne Corporation, formerly Techne Corporation, incorporated in 1976 and headquartered in Minneapolis, Minnesota, is a global developer, manufacturer, and seller of life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company's core mission is to accelerate scientific discovery and improve clinical diagnostics by providing innovative tools and solutions. Over the years, it has specialized particularly in the fields of protein science and genomics, helping researchers and clinicians understand complex biological processes and diagnose diseases more effectively. Bio-Techne continuously invests in R&D, aiming to deliver high-quality products that meet the needs of the scientific community.
The company operates through two primary segments: Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflows, consisting of manual and automated protein analysis instruments and immunoassays for quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. It also sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.
Bio-Techne serves a broad customer base globally. Its primary target demographics include scientists in academic and government research institutions, researchers in pharmaceutical and biotechnology companies, clinical laboratories, and diagnostic providers. The company's products are utilized in a wide array of fields, including cancer research, neurological diseases, immunology, stem cell research, and regenerative medicine. Its global presence is supported by strong distribution networks and direct sales teams across North America, Europe, and the Asia-Pacific regions. This extensive geographical reach allows the company to cater to customer needs in diverse markets and comply with local regulations. The company continuously aims to enter new markets and increase its share in existing ones.
Looking ahead, Bio-Techne plans to continue its growth through innovative product development and strategic acquisitions. It is particularly focused on expanding its capabilities in spatial biology, cell and gene therapy, and advanced diagnostics. The company aims to further enhance its products and services by leveraging emerging technologies such as artificial intelligence and machine learning. Furthermore, it intends to increase its manufacturing capacity and strengthen its supply chain to meet the growing demand in the global healthcare market. With a commitment to sustainable growth and shareholder value creation, Bio-Techne aims to solidify its leading position in the life sciences and diagnostics sector. This strategic direction will ensure the company's long-term success and impact in the industry.